A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of ...

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable ...

Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...

Panelists discuss how managing amivantamab-related adverse events such as leg edema requires understanding of underlying ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.